Enter your keywords

Polypharmacy – MO opportunities

Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]

Electronic repeat dispensing (eRD): medicines roadmap and outcomes of high eRD uptake

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees. This report provides a medicines roadmap to support the […]

NHS Medicines Optimisation Opportunities Dashboard

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]

North of England Integrated Care Systems; Overprescribing

This bulletin provides an update on key primary care prescribing trends in the North of England, which relate to ‘Overprescribing’; incorporating ‘Polypharmacy’. It provides a snapshot of overprescribing in the North of England Integrated Care Systems, including the percentage of patients receiving five or more unique analgesic medicines, and those receiving three unique medicines (not […]